logo-loader
viewOncimmune

Oncimmune signs major immune profiling contract with Swiss pharma giant Roche

The contract involves a substantial upfront payment said the AIM-listed group and starts immediately

Oncimmune -
Through biomarkers Oncimmune will assess how people react to cancer immunotherapy treatment

Oncimmune Holdings PLC (LON:ONC) said it has signed its largest contract to date with Swiss pharma giant Roche to profile auto-antibodies in patient samples collected during cancer immunotherapy trials.

The new contract follows an initial project between the companies over the past two months and will enable further assessment of individual patient responses to immunotherapy through immune profiling.

Using its SeroTag biomarker discovery platform, Oncimmune said it will explore baseline and on-treatment autoantibody profiles as biomarkers in patients that received cancer immunotherapy.

The contract involves a substantial upfront payment, added the AIM-listed group and starts immediately.

Initial results are scheduled to be provided to Roche within three months and the project to be completed by November.

In a statement, Adam Hill, Oncimmune’s chief executive said: "This significant contract with Roche not only builds upon the excellent collaborative work between the Oncimmune and Roche teams in recent months, but it strikes to the heart of understanding as to why cancer patients have differing responses to the same immunotherapy.

"Since acquiring Oncimmune Germany last year, we have grown the pipeline of potential commercial projects with major pharmaceutical and biotechnology companies, and this contract, the largest we have signed to date, provides further evidence of our ability to convert pipeline opportunities into contracted revenues.”

Quick facts: Oncimmune

Price: 123.01 GBX

AIM:ONC
Market: AIM
Market Cap: £78.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20

2 min read